Share-based Payment Arrangement, Expense of Moderna, Inc. from 31 Dec 2016 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Moderna, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2016 to 30 Sep 2025.
  • Moderna, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $125,000,000, a 12% increase year-over-year.
  • Moderna, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $474,000,000, a 17% increase year-over-year.
  • Moderna, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $429,000,000, a 41% increase from 2023.
  • Moderna, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $305,000,000, a 35% increase from 2022.
  • Moderna, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $226,000,000, a 59% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Moderna, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $474,000,000 $125,000,000 +$13,000,000 +12% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $461,000,000 $130,000,000 +$18,000,000 +16% 01 Apr 2025 30 Jun 2025 10-Q 01 Aug 2025 2025 Q2
Q1 2025 $443,000,000 $115,000,000 +$14,000,000 +14% 01 Jan 2025 31 Mar 2025 10-Q 01 May 2025 2025 Q1
Q4 2024 $429,000,000 $104,000,000 +$25,000,000 +32% 01 Oct 2024 31 Dec 2024 10-K 21 Feb 2025 2024 FY
Q3 2024 $404,000,000 $112,000,000 +$35,000,000 +45% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $369,000,000 $112,000,000 +$38,000,000 +51% 01 Apr 2024 30 Jun 2024 10-Q 01 Aug 2025 2025 Q2
Q1 2024 $331,000,000 $101,000,000 +$26,000,000 +35% 01 Jan 2024 31 Mar 2024 10-Q 01 May 2025 2025 Q1
Q4 2023 $305,000,000 $79,000,000 +$17,000,000 +27% 01 Oct 2023 31 Dec 2023 10-K 21 Feb 2025 2024 FY
Q3 2023 $288,000,000 $77,000,000 +$7,000,000 +10% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $281,000,000 $74,000,000 +$24,000,000 +48% 01 Apr 2023 30 Jun 2023 10-Q 01 Aug 2024 2024 Q2
Q1 2023 $257,000,000 $75,000,000 +$31,000,000 +70% 01 Jan 2023 31 Mar 2023 10-Q 02 May 2024 2024 Q1
Q4 2022 $226,000,000 $62,000,000 +$25,000,000 +68% 01 Oct 2022 31 Dec 2022 10-K 21 Feb 2025 2024 FY
Q3 2022 $201,000,000 $70,000,000 +$30,000,000 +75% 01 Jul 2022 30 Sep 2022 10-Q 03 Nov 2023 2023 Q3
Q2 2022 $171,000,000 $50,000,000 +$15,000,000 +43% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 $156,000,000 $44,000,000 +$14,000,000 +47% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q4 2021 $142,000,000 $37,000,000 +$11,000,000 +42% 01 Oct 2021 31 Dec 2021 10-K 23 Feb 2024 2023 FY
Q3 2021 $131,000,000 $40,000,000 +$18,000,000 +82% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $113,000,000 $35,000,000 +$10,000,000 +40% 01 Apr 2021 30 Jun 2021 10-Q 03 Aug 2022 2022 Q2
Q1 2021 $103,000,000 $30,000,000 +$10,000,000 +50% 01 Jan 2021 31 Mar 2021 10-Q 04 May 2022 2022 Q1
Q4 2020 $93,000,000 $26,000,000 +$5,796,000 +29% 01 Oct 2020 31 Dec 2020 10-K 24 Feb 2023 2022 FY
Q3 2020 $87,204,000 $22,000,000 +$1,196,000 +5.7% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021 2021 Q3
Q2 2020 $86,008,000 $25,000,000 +$3,505,000 +16% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $82,503,000 $20,000,000 +$1,503,000 +8.1% 01 Jan 2020 31 Mar 2020 10-Q 06 May 2021 2021 Q1
Q4 2019 $81,000,000 $20,204,000 -$11,437,000 -36% 01 Oct 2019 31 Dec 2019 10-K 25 Feb 2022 2021 FY
Q3 2019 $92,437,000 $20,804,000 +$6,084,000 +41% 01 Jul 2019 30 Sep 2019 10-Q 30 Oct 2020 2020 Q3
Q2 2019 $86,353,000 $21,495,000 +$7,142,000 +50% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020 2020 Q2
Q1 2019 $79,211,000 $18,497,000 +$6,646,000 +56% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $72,565,000 $31,641,000 01 Oct 2018 31 Dec 2018 10-K 26 Feb 2021 2020 FY
Q3 2018 $14,720,000 01 Jul 2018 30 Sep 2018 10-Q 06 Nov 2019 2019 Q3
Q2 2018 $14,353,000 01 Apr 2018 30 Jun 2018 10-Q 08 Aug 2019 2019 Q2
Q1 2018 $11,851,000 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019 2019 Q1

Moderna, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $429,000,000 +$124,000,000 +41% 01 Jan 2024 31 Dec 2024 10-K 21 Feb 2025 2024 FY
2023 $305,000,000 +$79,000,000 +35% 01 Jan 2023 31 Dec 2023 10-K 21 Feb 2025 2024 FY
2022 $226,000,000 +$84,000,000 +59% 01 Jan 2022 31 Dec 2022 10-K 21 Feb 2025 2024 FY
2021 $142,000,000 +$49,000,000 +53% 01 Jan 2021 31 Dec 2021 10-K 23 Feb 2024 2023 FY
2020 $93,000,000 +$12,000,000 +15% 01 Jan 2020 31 Dec 2020 10-K 24 Feb 2023 2022 FY
2019 $81,000,000 +$8,435,000 +12% 01 Jan 2019 31 Dec 2019 10-K 25 Feb 2022 2021 FY
2018 $72,565,000 +$32,510,000 +81% 01 Jan 2018 31 Dec 2018 10-K 26 Feb 2021 2020 FY
2017 $40,055,000 +$695,000 +1.8% 01 Jan 2017 31 Dec 2017 10-K 27 Feb 2020 2019 FY
2016 $39,360,000 01 Jan 2016 31 Dec 2016 10-K 13 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.